


The Preparation and Use of Metallo-6-vinylidene Penams

John D. Buynak,* H. B. Borate, Grady Lamb, Harold Isom, Chad Husting, and Dipti Khasnis

Department of Chemistry, Southern Methodist University, Dallas, TX 75275, U.S.A.


The parent unsubstituted 6-vinylidenepenam and various 6-acetylenic penams are shown to be available from corresponding allenyl iodides.

Selected 6-unsaturated penams have been shown to be excellent inhibitors of some types of β -lactamase.¹ Further interest in the use of penicillin-related species as enzyme inhibitors is fuelled by the recent discovery by workers at Merck that certain cepham esters are excellent elastase inhibitors.² As an expansion of our earlier work on the synthetic utility of allenes in the preparation of established β -lactamase inhibitors³ and our recognition of the many excellent allene-derived enzyme inhibitors,⁴ we earlier reported that α -vinylidene penams [e.g., (3)] could be prepared as shown in Scheme 1. The readily available 6-oxopenicillanic acid⁵ is sequentially treated with either lithium or cerium acetylide and then trifluoromethanesulphonic anhydride to yield the propynylic trifluoromethanesulphonates (2). These materials can then be treated with copper(i) halides in dimethylformamide (DMF) at room temperature to yield the corresponding allenyl halides [(3) Nu = X] or with certain higher order cuprates in tetrahydrofuran (THF) at -78°C to prepare the alkylated allenes [(3) Nu = alkyl]. We now report that the terminal iodovinylidenepenam is a versatile intermediate in the preparation of various 6-vinylidene derivatives of penicillin including the parent unsubstituted compound (5).†





Scheme 1. Reagents: i, H-C≡CM, then (CF₃SO₂)₂O, pyridine.

† Structure of key compounds confirmed by ¹H NMR, ¹³C NMR, IR, and HRMS.



Scheme 2. Reagents and conditions: i, Bu^sLi, then HOAc; ii, Zn/Cu, NH₄Cl; iii, MeMgBr, then HOAc; iv, Bu^sLi, then R¹COCl.



Scheme 3. Reagents and conditions: i, EtO₂CC≡CLi, then NH₄Cl; ii, (CF₃SO₂)₂O, then CuI, DMF; iii, EtMgBr, -78°C, then NH₄Cl.

As shown in Scheme 2, lithiation by treatment with *s*-butyllithium and quenching with acid produced the isomeric acetylenic (5) and vinylidene (6) penams. Conversely, treatment of iodoallene (4) with Zn/Cu couple in methanolic ammonium chloride led to the parent unsubstituted vinylidene penam (6). This material can also be prepared by reaction of iodoallene with methylmagnesium bromide followed by quenching the intermediate allenylmagnesium with acid. Acylation of the intermediate organolithium produced the 6-acyl-6-acetylenic penam [(7) R¹ = Me, *p*-MeC₆H₄, or *p*-MeOC₆H₄] in poor yield. Acylation of the allenylmagnesium intermediate was much slower but also produced the acetylenic compound (7) in low yield and not the terminally acylated derivative (8).

The dichotomy of behaviour towards protonation suggests that the organolithium intermediate might be best described as the enolate (9) or the 6-lithiopenam (10), while the magnesium and zinc derivatives appear to maintain their original allenic character as illustrated by structure (11). The acylation of the allenylmagnesium most likely occurs *via* the well precedented⁷ cyclic pathway illustrated in structure (A).

Since we also desired to prepare the terminally acylated allenenes as potential enzyme inhibitors, we considered incorporating such functionality as a portion of the acetylene. In this regard, our previously described methodology for the formation and reduction of the halo allenenes proved useful. As shown in Scheme 3, the ethyl propiolate anion can be added to 6-oxopenicillanic ester to produce the propynyl alcohol (12), which was converted to allenyl iodide (13). Treatment of the allenyl iodide with Bu^sLi and quenching with a proton source

yielded a 1:1 mixture of diastereoisomers of the desired allenic ester (14).

These and related compounds are being explored as inhibitors of several classes of enzymes. The results will be reported shortly.

We thank the National Institute of Health, American Cyanamid, and the Robert A. Welch Foundation for generous financial support of this research.

Received, 21st August 1989; Com. 9/03565F

References

- 1 Y. L. Chen, C. W. Chang, K. Hedberg, K. Guarino, W. M. Wesch, L. Kiessling, J. A. Retsma, S. L. Haskell, M. Anderson, M. Manousos, and J. F. Barrett, *J. Antibiot.*, 1987, **40**, 803.
- 2 J. B. Doherty, B. M. Ashe, L. W. Argenbright, P. L. Barker, R. J. Bonney, G. O. Chandler, M. E. Dahlgren, C. P. Dorn, Jr., P. E. Finke, R. A. Firestone, D. Fletcher, W. K. Hagmann, R. Mumford, L. O'Grady, A. L. Maycock, J. M. Pisano, S. K. Shah, K. R. Thompson, and M. Zimmermann, *Nature*, 1986, **322**, 192; M. A. Navia, J. P. Springer, T. Y. Lin, H. R. Williams, R. A. Firestone, J. M. Pisano, J. B. Doherty, P. E. Finke, and K. Hoogsteen, *ibid.*, 1987, **327**, 79.
- 3 J. D. Buynak, J. Mathew, and M. N. Rao, *J. Chem. Soc., Chem. Commun.*, 1986, 941; J. D. Buynak and M. N. Rao, *J. Org. Chem.*, 1986, **51**, 1571.
- 4 R. P. Halliday, C. S. Davis, J. P. Heotis, D. T. Pals, E. J. Watson, and R. K. Bickerton, *J. Pharm. Sci.*, 1968, **57**, 430; M. Morisaki and K. Bloch, *Biochemistry*, 1972, **11**, 309; D. F. Covey and C. H. Robinson, *J. Am. Chem. Soc.*, 1976, **98**, 5038; E. J. Corey and J. Kang, *Tetrahedron Lett.*, 1982, **23**, 1651; A. L. Castelhamo, D. H. Pliura, G. J. Taylor, K. C. Hsieh, and A. Krantz, *J. Am. Chem. Soc.*, 1984, **106**, 2734; M. J. Jung, J. G. Haydt, and P. Casara, *Biochem. Pharm.*, 1984, **33**, 3717; C. Danzin and P. Casara, *FEBS Lett.*, 1984, **174**, 275; C. Sahlberg, S. B. Ross, I. Fagervall, A. L. Ask, and A. Claesson, *J. Med. Chem.*, 1983, **26**, 1036.
- 5 J. D. Buynak, H. B. Borate, C. Husting, T. Hurd, J. Vallabh, J. Matthew, J. Lambert, and U. Siriwardane, *Tetrahedron Lett.*, 1988, **29**, 5053.
- 6 For references to the use of 6-metallopenams and related compounds see: F. DiNinno, T. R. Beattie, and B. G. Christensen, *J. Org. Chem.*, 1977, **42**, 2960; D. K. Pirie, W. M. Welch, P. D. Weeks, and R. A. Volkmann, *Tetrahedron Lett.*, 1986, **27**, 1549; R. G. Micetich, S. N. Maiti, M. Tanaka, T. Yamazaki, and K. Ogawa, *J. Org. Chem.*, 1986, **51**, 853; R. A. Firestone, N. S. Maciejewicz, R. W. Ratcliffe, and B. G. Christensen, *ibid.*, 1974, **39**, 437; E. H. W. Bohme, H. E. Applegate, J. B. Ewing, P. T. Funke, M. S. Puar, and J. E. Dolfini, *ibid.*, 1973, **38**, 230; D. I. John, N. D. Tyrrell, and E. J. Thomas, *Tetrahedron*, 1983, **39**, 2477.
- 7 D. Hoppe, C. Gonschorrek, D. Schmidt, and E. Egert, *Tetrahedron*, 1987, **43**, 2457; R. Couffignal and M. Gaudemar, *Bull. Soc. Chim. Fr.*, 1969, 898; J. Pansard and M. Gaudemar, *ibid.*, 1968, 3332; 'The Chemistry of the Allenes,' ed. S. R. Landor, Academic Press, New York, 1982; J. L. Moreau, in 'The Chemistry of Ketenes, Allenes, and Related Compounds,' ed. S. Patai, Wiley, Chichester, 1980, part 1, ch. 10.